Source: International Congress 2018 – Clinical markers of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Petersen (Aalborg, Denmark), U. MøLler Weincreich (Aalborg, Denmark). Incremental cost-effective ratio effect of Omalizumab treatment for Severe Allergic Asthma at Danish university Hospital.. 4000

Member's Comments

No comment yet.

Related content which might interest you: Guideline adherence and cost of asthma treatment at emergency department Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies Source: International Congress 2014 – More paediatric asthma Year: 2014 Finding asthmatics suitable for omalizumab therapy in a district hospital Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013 Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Serious asthma exacerbations in a hospital setting Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Comparative effectiveness of paediatric asthma step-up options: Increasing ICS dose vs adding separate LABA Source: International Congress 2014 – Paediatric asthma: what is new for the clinician? Year: 2014 A multidisciplinary clinic for children with severe asthma: Clinical outcomes and healthcare utilization Source: International Congress 2014 – More paediatric asthma Year: 2014 LATE-BREAKING ABSTRACT: Impact of Asthma, Allergic Rhinitis, COPD and Rhinosinusitis on healthcare resource utilization in Asia Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Allergic rhinitis does it have an impact on controller asthma therapy choice Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Predictors of BTS Step 3 paediatric asthma prescribing Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 White Coat Adherence in children with asthma enrolled in a comprehensive asthma management program Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 The impact of a specialist multi-disciplinary approach on burden of frequent asthma admissions Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016 Use of β-blockers and the risk of asthma exacerbations Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Swiss Severe Asthma Registry (SSAR)- Good asthma control and high number of exacerbations. How does this fit? Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Metered-dose inhaler albuterol: Evaluation of efficacy and safety of increasing doses in children with acute wheezing Source: International Congress 2014 – Paediatric asthma: lung function testing and more Year: 2014 Cost Effectiveness Of Bronchial Thermoplasty For Treatment Of Severe Asthma Patients In Scotland Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry Source: Eur Respir J, 56 (6) 2002857; 10.1183/13993003.02857-2020 Year: 2020 Triple combination therapy in severe asthma: overview from the Italian Registry Severe Asthma (IRSA) Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021